MOUNTAIN VIEW, CA--(Marketwire - March 09, 2011) - Therapeutic peptides are one of the most attractive options in recombinant medicine. Due to their low toxicity, high specificity and much lower molecular weight, it is easier to set up dosage plans for patients. Although therapeutic peptides entered the market twenty years ago, they witnessed greater uptake during the past five or six years. Improvements in the manufacturing process and delivery systems triggered a revival of interest among consumers.
New analysis from Frost & Sullivan (http://www.technicalinsights.frost.com), Advances in Peptide Therapeutics, finds that in view of the recent revival, budgeting is the most crucial element for the R&D portfolio aspect of therapeutic peptides.
If you are interested in a virtual brochure on this study, please send an e-mail to Sarah Saatzer, Corporate Communications, at sarah.saatzer@frost.com, with your full name, company name, job title, telephone number, company e-mail address, company website, city, state and country.
“Emerging therapeutic areas for peptides such as anti-infectives, vaccines and CNS-targeting peptides can well set the stage for a new class of drugs in these areas,” notes Technical Insights senior research analyst Ipshita Chakraborty. “Several large pharmaceutical companies avidly fund detailed research in this field.”
With peptide therapeutics poised for a boost with high funding inflows and collaboration between big pharmaceuticals, small biotechs, academia and contract manufacturing organizations, a major point of concern is effective portfolio design to take advantage of the therapeutic areas that have the highest market potential.
Portfolio management approaches differ among stakeholders. Small biotech companies focus on a single product or technology, while big pharmaceutical companies maintain a diverse portfolio by therapeutic area and focus on collaborations, mergers and acquisitions (M&A) and licensing. This creates a gap in stakeholder interconnections in this industry.
Cost-intensive manufacturing processes present barriers for small biotech companies that can synthesize peptides, but cannot get to the stage of market entry. Lastly, alternative de-risking approaches such as small molecules can be better for some diseases, therefore, restricting the entry of therapeutic peptides in that area.
Nevertheless, peptide therapeutics hold huge promise from a medical point of view for both patients and drug companies. Cost optimization in manufacturing and the development of non-invasive delivery technologies will go a long way in generating strong revenue growth for this sector and lead to better treatment outcomes for the patient.
“Efficient target discovery platforms and further research on peptide stability will greatly assist the manufacturing process,” concludes Chakraborty. “The advent of new manufacturing methods in solid-phase production will help scale down the production cost for peptides.”
Advances in Peptide Therapeutics, a part of the Technical Insights subscription, provides an overview of the peptide therapeutics industry, the major stakeholders, the market drivers and challenges and a prioritized recommendation for R&D portfolio design. Further, this research service includes detailed technology analysis and industry trends evaluated following extensive interviews with market participants.
Technical Insights is an international technology analysis business that produces a variety of technical news alerts, newsletters, and research services.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company’s Growth Partnership Service provides the CEO and the CEO’s Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.
Advances in Peptide Therapeutics
D21C
